NEUMORA THERAPEUTICS, INC. (NMRA) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-180.52M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | -0.69× | Operating cash flow / net income. Period ending 2026-06-30. $-180.52M ÷ $261.11M ≈ -0.69× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -180.52M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | (m) | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | 261.11M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $-180.52M | (m) | (m) | (m) | (m) | $261.11M | (m) | (m) | (m) | -0.69× |
| 2026-03-31 | (m) | (m) | $-193.40M | (m) | (m) | (m) | (m) | $251.46M | (m) | (m) | (m) | -0.77× |
| 2025-12-31 | (m) | (m) | $-206.44M | (m) | (m) | (m) | (m) | $-236.93M | (m) | (m) | (m) | 0.87× |
| 2025-09-30 | (m) | (m) | $-208.82M | (m) | (m) | (m) | (m) | $-236.30M | (m) | (m) | (m) | 0.88× |
| 2025-06-30 | (m) | (m) | $-195.68M | (m) | (m) | (m) | (m) | $-252.09M | (m) | (m) | (m) | 0.78× |
| 2025-03-31 | (m) | (m) | $-199.43M | (m) | (m) | (m) | (m) | $-258.06M | (m) | (m) | (m) | 0.77× |
| 2024-12-31 | (m) | (m) | $-182.94M | (m) | (m) | (m) | (m) | $-243.79M | (m) | (m) | (m) | 0.75× |
| 2024-09-30 | (m) | (m) | $-184.04M | (m) | (m) | (m) | (m) | $-293.70M | (m) | (m) | (m) | 0.63× |
| 2024-06-30 | (m) | (m) | $-198.33M | (m) | (m) | (m) | (m) | $-274.18M | (m) | (m) | (m) | 0.72× |
| 2024-03-31 | (m) | (m) | $-173.19M | (m) | (m) | (m) | (m) | $-254.02M | (m) | (m) | (m) | 0.68× |
| 2023-12-31 | $-163.40M | (m) | $-163.28M | $117.00K | (m) | (m) | (m) | $-235.93M | (m) | (m) | (m) | 0.69× |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-123.49M | (m) | (m) | (m) | (m) |
| 2022-12-31 | $-115.41M | (m) | $-114.90M | $511.00K | (m) | (m) | (m) | $-130.90M | (m) | (m) | (m) | 0.88× |
| 2022-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |